Abbott Laboratories (ABT) Short-term Investments (2009 - 2026)

Abbott Laboratories has reported Short-term Investments for 18 years, with the latest figure at $499.0 million in Q2 2026.

• Quarterly Short-term Investments rose 50.76% year-over-year to $499.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $499.0 million (up 50.76% YoY) and the FY2025 annual result came in at $417.0 million, up 18.8% from the prior year.
• Short-term Investments climbed to $499.0 million in Q2 2026 per ABT's latest filing, from $492.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $499.0 million in Q2 2026 and troughed at $222.0 million in Q3 2025.
• A 5-year average of $350.1 million and a median of $344.5 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2026: Short-term Investments sank 36.0% in 2022, then jumped 57.69% in 2026.
• Over 5 years, Short-term Investments stood at $288.0 million in 2022, then surged by 32.99% to $383.0 million in 2023, then slipped by 8.36% to $351.0 million in 2024, then gained by 18.8% to $417.0 million in 2025, then advanced by 19.66% to $499.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $499.0 million, $492.0 million, and $417.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.